Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 2 de 2
Filter
Add more filters

Database
Language
Affiliation country
Publication year range
1.
Diagnostics (Basel) ; 12(12)2022 Nov 26.
Article in English | MEDLINE | ID: mdl-36552967

ABSTRACT

In recent years, due to the development of standardized diagnostic protocols associated with an improvement in the associated technology, the diagnosis of pelvic endometriosis using imaging is becoming a reality. In particular, transvaginal ultrasound and magnetic resonance are today the two imaging techniques that can accurately identify the majority of the phenotypes of endometriosis. This review focuses not only on these most common imaging modalities but also on some additional radiological techniques that were proposed for rectosigmoid colon endometriosis, such as double-contrast barium enema, rectal endoscopic ultrasonography, multidetector computed tomography enema, computed tomography colonography and positron emission tomography-computed tomography with 16α-[18F]fluoro-17ß-estradiol.

2.
Expert Opin Drug Metab Toxicol ; 8(7): 901-8, 2012 Jul.
Article in English | MEDLINE | ID: mdl-22681335

ABSTRACT

INTRODUCTION: Progesterone (P), and its receptors (PRs), play a key role in uterine leiomyoma growth. Selective progesterone receptor modulators exert mixed antagonist and agonist effects on the PRs. Mifepristone, a PR-antagonist, reduces leiomyoma volume and related symptoms. Ulipristal acetate (UPA) exerts a potent antiprogestin activity, with less antiglucocorticoid activity compared to mifepristone. This property provides potential advantages for long-term use. AREAS COVERED: This paper focuses on the effect of UPA on leiomyoma's growth and related symptoms in women. The authors also evaluate UPA's efficacy in reducing leiomyoma's size and menorrhagia in Phase II/III trials. EXPERT OPINION: In the authors' opinion, UPA (5 mg/day) over 3 months can be used to plan the surgery in women with symptomatic leiomyomas. The tolerability and the safety of treatment over a period longer than 3 months have to be evaluated. The results of the follow-up treatment suggest that further studies could successfully evaluate the efficacy and the tolerability of intermittent 3-month courses of treatment.


Subject(s)
Drug Evaluation, Preclinical/methods , Leiomyoma/drug therapy , Norpregnadienes/pharmacology , Norpregnadienes/pharmacokinetics , Uterine Neoplasms/drug therapy , Adult , Clinical Trials, Phase II as Topic , Clinical Trials, Phase III as Topic , Female , Hormone Antagonists/therapeutic use , Humans , Leiomyoma/surgery , Menorrhagia/drug therapy , Mifepristone/therapeutic use , Progesterone/metabolism , Receptors, Progesterone/antagonists & inhibitors , Receptors, Progesterone/metabolism , Uterine Neoplasms/surgery
SELECTION OF CITATIONS
SEARCH DETAIL